Navigation Links
Accera, Inc. Elects Industry Veteran Holger Kunze as CEO and as a Member of the Company's Board of Directors
Date:1/3/2012

BROOMFIELD, Colo., Jan. 3, 2012 /PRNewswire/ -- Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative therapeutics to treat central nervous system disorders, announced today that Holger Kunze has been appointed to the position of Chief Executive Officer and as a member of the company's Board of Directors (BoD).  Concurrently, Sven Thormahlen, Ph.D., has also been appointed as a member of Accera's BoD.

With more than 30 years managerial experience with multinational pharmaceutical and nutrition companies, Mr. Kunze currently serves as the Regional Business Unit Head for Nestle Health Science's HealthCare Nutrition Business Unit in the Africa, Oceania and Asia (AOA) territories.  While managing more than 600 employees, Mr. Kunze integrated the Novartis Medical Nutrition Business into the Nestle Nutrition Division, leading it to one of the top Medical Nutrition companies in the region with more than $250M in sales for 2011.  Under his leadership, Nestle Health Science consistently delivered annual targeted top and bottom line performance and gained market share in all markets.

Prior to joining Nestle, Mr. Kunze held various managerial positions within Novartis for more than 10 years.  Most recently, Mr. Kunze led and managed the consumer health division of the Asia Regional Novartis Medical Nutrition business unit from 2004 to 2007.  During his tenure, Mr. Kunze established the Asia Regional Medical Nutrition Office in Singapore, supported and coordinated the acquisition of the Mead Johnson Adult Nutrition business and led and managed the Medical Nutrition businesses for Novartis in 17 Asian countries. 

"I am thrilled to have the opportunity to add to Accera's efforts of providing Alzheimer's patients with an alternative for managing their disease," said Mr. Kunze.  "I'm confident that with my experience, we'll be able to further expand the commercial presence of Axona in global markets."

Dr. Sven Thormahlen has more than twenty years experience in successfully managing industrial research and product development departments with emphasis on fast moving consumer goods, medical devices, OTC products and medical nutrition.  He currently serves as the CEO of MucoVax, a biological immune care company based in Germany.  Prior to this role, Dr. Thormahlen served as the International executive director of research and development at Groupe Danone in France until May 2011.  In this role, Dr. Thormahlen headed more than 1,500 researchers while overseeing four divisions, including medical nutrition, dairy foods, waters and beverages and baby and infant nutrition.

"We are delighted to be joined by Mr. Kunze and Dr. Thormahlen," said Claude Nash, Ph.D., head of Accera's BoD.  "We are confident their extensive experience with international pharmaceutical companies and medical nutrition will further Accera's goal of developing novel therapeutic products for neurodegenerative diseases."

About Axona®
Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. For more information about Axona, please visit www.about-axona.com or ask your physician.

About Accera, Inc.
Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US.  Accera is engaged in the research, development and commercialization of other clinical applications for Axona and AC-1204 in acute and chronic neurodegenerative diseases.  For more information about Accera, please visit www.accerapharma.com.Contacts:  

Tiberend Strategic Advisors, Inc.Accera, Inc.

(212) 827-0020(303) 999-3705

Andrew MielachBill Poncy

amielach@tiberend.comVP Commercial Development

or bponcy@accerapharma.com

Stephanie Denis 

sdenis@tiberend.com 


'/>"/>
SOURCE Accera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accera, Inc. Appoints Dr. Thomas Werner President & CEO and Announces FDA Acceptance of IND Application for AC-1204 for Mild-to-Moderate Alzheimers Disease
2. Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference
3. Inova Selects Beryl as Provider of Outsourced Patient Experience Solutions
4. WHCA Selects COMS Interactive as Affinity Partner
5. Tidewell Hospice Selects Allscripts Homecare and Financial Management Solutions
6. Top 3 Clinical Research Organization Selects QTinno for a Phase I Drug Safety Trial
7. Alabama Selects Thomson Reuters HIE Advantage™ for Statewide Health Information Exchange
8. The Association of Telecom Professionals Selects Dr. Jay Yadav, CardioMEMS Founder & CEO, as an Atlanta Telecom Professional of the Year in the Industry Innovation Category
9. DMC Childrens Hospital of Michigan Selects Allscripts Electronic Health Record for Employed and Affiliated Physicians
10. Brown & Toland Physicians Selects Allscripts Community Record to Connect 1,500 Bay Area Physicians
11. WhiteGlove Health Selects HealthWarehouse.com to Provide Prescription Medications to its Members Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... and PETACH TIKVAH, Israel , ... (NASDAQ: BCLI), a leading developer of adult stem cell ... June S. Almenoff , M.D., Ph.D., FACP, and ... Board of Directors.  "Dr. Almenoff and ... appointments come at an exciting time for our company," ...
(Date:2/24/2017)... Following receiving CE Marking in ... AMAR is a major milestone for the country where the device was ... market in Israel   ... for inclusion in the National Health Basket , Israel ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced ...
(Date:2/24/2017)... , Feb 24, 2017 Research and Markets ... Strategies - 2016" report to their offering. ... The latest research Hemophilia Drugs Price Analysis and ... Hemophilia market. The research answers the following questions: ... clinical attributes? How are they positioned in the Global Hemophilia market? ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... Only two months after the official release of The Private ... (France), XO Private has initiated a second print-run of its lavish luxury travel coffee ... across when open, weighs in at more than six kilos, retails at EUR 1,000 ...
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... ... With millions of Americans and people worldwide struggling with ... aware of our options and are empowered with strength and information throughout the ... newest edition of "Vision and Hearing" in USA Today, that will educate readers ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users ... X . Users have total control over position, rotation, distortion, edge softness, edge blur, ... Final Cut Pro X. , With ProGlass Prism users are given the tools ...
(Date:2/24/2017)... IL (PRWEB) , ... February 24, 2017 , ... The ... the 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. ... Choice will be showcased and the winner revealed at the 31st annual iaedp Symposium, ...
Breaking Medicine News(10 mins):